Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Perrigo’s Mucinex Equivalent On The Cusp, But New Product Outlook Dims

This article was originally published in The Tan Sheet

Executive Summary

The private labeler’s long-delayed guaifenesin launch now tentatively is set for March, CEO Joseph Papa says. But unclear timelines for other OTC launches caused Perrigo to lower its fiscal year consolidated new product sales outlook to $150 million from an initial projection of more than $190 million.

Advertisement

Related Content

Perrigo Ships Guaifenesin/PSE Tablets, But Single-Ingredient Snags Linger
With Generic Mucinex Delayed, Perrigo Will Need Alternatives To Drive Sales Growth
“Perfect Storm” Flattens Perrigo Consumer Sales, Cuts Income 57%
Perrigo Sets Strategy For Global Infant Formula Growth
Perrigo Launch Investments Hold Income Back, As Firm Girds For 2013
Dr. Reddy’s Projects 50% Growth In U.S. OTC Business

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS106212

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel